Bislang kein wirklicher Durchbruch - Biologika bei chronisch entzündlichen Darmerkrankungen

Zusammenfassung

In den letzten Jahren wurden zahlreiche Studien zur Wirkung von Biologika bei chronisch entzündlichen Darmerkrankungen durchgeführt. Mit Ausnahme von Infliximab und anderen Tumornekrosefaktor-Antikörpern hat sich bisher keines der Prinzipien als hinreichend erfolgreich erwiesen, um in die Praxis überführt zu werden. Der Integrin-Antikörper Natalizumab zum Beispiel ist wegen Nebenwirkungsproblemen sogar vom Markt genommen worden. Bei Betrachtung der Studien zeigt sich, dass häufig die falschen Patienten eingeschlossen wurden, gelegentlich auch übersehen wurde, dass die Hemmung eines einzelnen Mediators aus einem redundanten Netzwerk nicht wirklich erfolgversprechend ist. Somit ist festzuhalten, dass Infliximab unser therapeutisches Arsenal bereichert hat, zumal es auch bei der Colitis ulcerosa bei etlichen Patienten wirksam ist, dass aber ein wirklicher Durchbruch in der Therapie durch die Biologika bislang nicht erfolgt ist.

Summary

During the last years numerous studies on the effects of biologics in chronic inflammatory bowel disease have been performed. With the exception of infliximab and some other tumor necrosis factor antibodies none of the principles has been sufficiently successful to be included in the routine armamentarium. The integrin antibody natalizumab has been retracted from the market due to serious side effects. When looking at the studies it becomes obvious that often wrong patients have been included into the trials and sometimes it has been overlooked that the inhibition of a signal mediator out of a redundant network is not really promising. Thus, we can conclude that infliximab has enriched our therapeutic arsenal, in particular since it also works in ulcerative colitis in a number of patients. However, the real breakthrough in the therapy has not yet been achieved by biologics.

chronic inflammatory bowel diseases - biologics - Crohn's disease - ulcerative colitis - tumor necrosis factor - hormones - cytokines

Literatur

• 1 Colombel JF, Loftus Jr EV, Tremaine WJ. et al. . The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients.  Gastroenterology. 2004;  126 19-31
• 2 Creed TJ, Norman MR, Probert CSJ. et al. . Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis.  Aliment Pharmacol Ther. 2003;  18 65-75
• 3 Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor.  Lancet. 2002;  360 1478-1480
• 4 Faubion Jr WA, Loftus Jr EV, Harmsen WS. et al. . The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.  Gastroenterology. 2001;  121 255-260
• 5 Feagan B, Greenberg GR, Wild G. et al. . Treatment of ulcerative colitis with a humanized antibody to the a4b7 integrin.  N Engl J Med. 2005;  352 2499-2507
• 6 Feagan BG, Greenberg G, Wild G. et al. . Efficacy and safety of a humanized a4b7 antibody in active Crohn's disease (CD).  Gastroenterology. 2003;  124 A25-A26
• 7 Gasché C, Schölmerich J, Brynskow J. et al. . A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.  Inflamm Bowel Dis. 2000;  6 8-15
• 8 Ghosh S, Goldin E, Gordon FH. et al. . Natalizumab for active Crohn's disease.  N Engl J Med. 2003;  348 24-32
• 9 Hanauer S, Lukas M, MacIntosh D. et al. . A randomized, double-blind, placebo-controlled trial of the human anti-TNF-a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease.  Gastroenterology. 2004;  127 332
• 10 Hanauer SB, Feagan BG, Lichtenstein GR. et al. . Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.  Lancet. 2002;  359 1541-1549
• 11 Herrlinger K, Witthoeft T, Raedler A. et al. . Randomized, double-blind, double-dummy, controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease.  Gastroenterology. 2004;  126 A466
• 12 Hommes DW, Mikhajlova TL, Stoinov S. et al. .Fontolizumab, a humanized anti-interferon-gamma antibody, demonstrates safety and clinical activity in patients with moderate-to-severe Crohn's disease. Gut, im Druck
• 13 Ito H, Takazoe M, Fukuda Y, Hibi T. et al. . A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.  Gastreoenterology. 2004;  126 989-996
• 14 Jess T, Loftus Jr EV, Harmsen WS. et al. .Survival and cause-specific mortality in patients with inflammatory bowel disease: A long-term outcome study in Olmsted County, Minnesota, 1940-2004. Gut, im Druck
• 15 Korzenik JR, Dieckgraefe BK, Valentine JF. Duration of sargramostim effects in patients with moderately-to-severely active Crohn's disease (CD): follow-up results from a randomized, double-blind, placebo-controlled trial.  Gastroenterology. 2004;  126 A75-A76
• 16 Korzenik JR, Dieckgraefe BK. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease.  Dig Dis Sci. 2000;  45 1121-1129
• 17 Ljung T, Karlen P, Schmidt D. et al. . Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.  Gut. 2004;  53 849-853
• 18 Loefberg R, Neurath M, Ost A, Pettersson S. Topical NFkB p65 antisense oligonucleotides in patients with active distal colonic IBD. A randomised, controlled pilot trial.  Gastroenterology. 2002;  122 A60
• 19 MacInthosh DG, Lukas M, Sandborn W. et al. . A randomized, double blind, placebo-controlled trial of the clinical assessment of adalimumab safety and efficacy studied as an induction therapy in Crohn's disease (classic).  Gut. 2004;  53 A47
• 20 Mannon PJ, Fuss IJ, Mayer L. et al. . Anti-interleukin-12 antibody for active Crohn's disease.  N Engl J Med. 2004;  351 2069-2079
• 21 Miner PB, Bane B, Bradley JD. et al. . ICAM-1 antisense inhibition by enema improves pouchitis and suggests long-term mucosal healing in patients with chronic unremitting disease.  Am J Gastroenterol. 2003;  98 S246-S247
• 22 Musch E, Andus T, Kruis W. et al. . Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial.  Clin Gastroenterol Hepatol. 2005;  3 581-586
• 23 Nikolaus S, Rutgeerts P, Fedorak R. et al. . Interferon b-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study.  Gut. 2003;  52 1286-1290
• 24 Sandborn W, Colombel JF, Enns R. et al. . A phase III, double-blind, placebo-controlled study of the efficacy, safety and tolerability of antegren (natalizumab) in maintaining clinical response and remission in Crohn's disease (ENACT-2).  Gastroenterology. 2004;  127 332
• 25 Sandborn WJ, Loftus EV. Balancing the risk and benefits of infliximab in the treatment of inflammatory bowel disease.  Gut. 2004;  53 780-782
• 26 Sandborn WJ, Sands BE, Wolf DC. et al. . Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial.  Aliment Pharmacol Ther. 2003;  17 1355-1364
• 27 Sands BE, Blank MA, Patel K. et al. . Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II study.  Clin Gastroenterol Hepatol. 2004;  2 912-920
• 28 Sands BE, Kozarek RA, Spainhour J. et al. . Safety and tolerability of natalizumab in patients concurrently receiving infliximab in a phase II study of active Crohn's disease.  Gastroenterology. 2004;  126 A463
• 29 Schölmerich J, Huber G. Biological therapy in IBD.  Dig Dis. 2003;  21 180-191
• 30 Schölmerich J. Biological therapies. In: Bernstein C (Hrsg). IBD-yearbook 2005
• 31 Schölmerich J. IBD - Pandora's box - present and future. N Y Acad Sci, im Druck
• 32 Schreiber S, Rutgeerts P, Fedorak RN. et al. . A randomized, placebo-controlled trial of Certolizumab Pegol (CDP870) for treatment of Crohn's disease.  Gastroenterology. 2005;  129 807-818
• 33 Sinha A, Nightingale J, West KP. et al. . Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.  N Engl J Med. 2003;  349 350-357
• 34 Slonim AE, Bulone L, Damore MB. et al. . A preliminary study of growth hormone therapy for Crohn's disease.  N Engl J Med. 2000;  342 1633-1637
• 35 Tilg H, Vogelsang H, Ludwiczek O. et al. . A randomized placebo controlled trial of pegylated interferon a in active ulcerative colitis.  Gut. 2003;  52 1728-1733
• 36 Van Assche G, van Ranst M, Sciot R. et al. . Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.  N Engl J Med. 2005;  353 362-368
• 37 Van Deventer SJH, Tami JA, Wedel MK. European Colitis Study Group . A randomized, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.  Gut. 2004;  53 1646-1651
• 38 Vaughan D, Drumm B. Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease.  N Engl J Med. 1999;  340 239-240
• 39 Winther KV, Jess T, Langholz E. et al. . Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen county.  Gastroenterology. 2003;  125 1576-1582

1 A Crohn's disease Clinical study Evaluating infliximab in a New long term Treatment regimen

Anschrift des Verfassers